Journal
FEBS LETTERS
Volume 585, Issue 23, Pages 3699-3709Publisher
WILEY
DOI: 10.1016/j.febslet.2011.03.023
Keywords
Tocilizumab; A humanized anti-IL-6 receptor antibody; IL-6; Autoimmune diseases; Inflammation
Funding
- National Institute of Biomedical Innovation
Ask authors/readers for more resources
Interleukin (IL)-6 is a cytokine with multiple biological activities. It contributes to host defense against pathogens, whereas accelerated production of IL-6 plays a significant pathological role in various diseases. Clinical trials have demonstrated the efficacy of tocilizumab, a humanized anti-IL-6 receptor antibody, for patients with rheumatoid arthritis, Castleman's disease or juvenile idiopathic arthritis, leading to approval of this innovative drug for the treatment of these diseases. Since IL-6 has been demonstrated to play a significant role in the development of various other autoimmune and inflammatory diseases, tocilizumab can be expected to become a novel drug for such diseases as well. (C) 2011 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available